31 Mar 2023
05 Apr 2023
₹ 25.31 Cr
17 Apr 2023
₹ 135 per share
The Company was incorporated with the objective of manufacturing and supplying of various pharma related chemicals, bulk drugs, pharma intermediates etc. It deals specifically and mainly in manufacturing and supplying of Iodine Derivatives, Pharma Intermediates and Active Pharmaceutical Ingredients (APIs).
The IPO comprises of fresh issue of 1,875,000 equity shares aggregating the issue size upto Rs. 25.31cr.
The objective of the Infinium Pharmachem IPO : The net proceeds from the issue will be used for: 1. Marketing and branding expenses (including registration in reach - Europe, and other marketing expenses) 2. Repayment of some of the existing loans and expansion of units 3. To meet incremental working capital requirements 4. To meet public issue expenses
The Infinium Pharmachem IPO lot size is 1000 shares. A retail-individual investor can apply for up to 1 lots (1000 shares or ₹135,000).
The allotment date of Infinium Pharmachem IPO is set for 11th April.
Infinium Pharmachem IPO is promoted by Mr. Mayank Shah.
Unistone Capital Private Limited is the book running lead managers to the issue.